474 reports of this reaction
1.8% of all DARUNAVIR reports
#14 most reported adverse reaction
VIROLOGIC FAILURE is the #14 most commonly reported adverse reaction for DARUNAVIR, manufactured by Janssen Products LP. There are 474 FDA adverse event reports linking DARUNAVIR to VIROLOGIC FAILURE. This represents approximately 1.8% of all 26,718 adverse event reports for this drug.
Patients taking DARUNAVIR who experience virologic failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIROLOGIC FAILURE is a less commonly reported adverse event for DARUNAVIR, but still significant enough to appear in the safety profile.
In addition to virologic failure, the following adverse reactions have been reported for DARUNAVIR:
The following drugs have also been linked to virologic failure in FDA adverse event reports:
VIROLOGIC FAILURE has been reported as an adverse event in 474 FDA reports for DARUNAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIROLOGIC FAILURE accounts for approximately 1.8% of all adverse event reports for DARUNAVIR, making it a notable side effect.
If you experience virologic failure while taking DARUNAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.